Metastatic melanoma: A regional review and future directions

Tumori

Volumn 98, Issue 5, 2012, Pages 575-580

  Khan, Khurum H ^a   Goody, Rebecca B ^b   Hameed, Hassan ^b   Jalil, Awais ^b   Coyle, Vicky M ^b   McAleer, James J A ^b  

^a ROYAL MARSDEN HOSPITAL   (United Kingdom)

^b BELFAST CITY HOSPITAL   (United Kingdom)

Author keywords

Dacarbazine; Ipilimumab; Metastatic melanoma; Temozolomide; Vemurafenib; Vinblastine

Indexed keywords

DACARBAZINE; TEMOZOLOMIDE; VINBLASTINE;

ADULT; AGED; BRAIN METASTASIS; CANCER LOCALIZATION; CANCER SCREENING; CANCER SURVIVAL; CONTROLLED STUDY; DISEASE ASSOCIATION; DRUG CYTOTOXICITY; DRUG EFFECT; DRUG EFFICACY; DRUG FATALITY; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; ELECTROCORTICOGRAPHY; EYE CANCER; FEMALE; FOLLOW UP; HUMAN; LIVER METASTASIS; LUNG METASTASIS; MAJOR CLINICAL STUDY; MALE; METASTATIC MELANOMA; MOUTH CANCER; MULTIPLE CYCLE TREATMENT; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PROGRESSION FREE SURVIVAL; REVIEW; SEX DIFFERENCE; SKIN CANCER; SYSTEMIC THERAPY; VISCERAL METASTASIS;

ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC AGENTS, ALKYLATING; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BRAIN NEOPLASMS; CLINICAL TRIALS AS TOPIC; CTLA-4 ANTIGEN; DACARBAZINE; DISEASE PROGRESSION; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; INCIDENCE; INTERLEUKIN-2; LYMPHATIC METASTASIS; MALE; MELANOMA; MIDDLE AGED; MUTATION; PREVALENCE; PROTO-ONCOGENE PROTEINS B-RAF; RETROSPECTIVE STUDIES; SKIN NEOPLASMS; TREATMENT OUTCOME; VINBLASTINE;

EID: 84872104351     PISSN: 03008916     EISSN: 20382529     Source Type: Journal    
DOI: 10.1177/030089161209800506     Document Type: Review

References (28)

1. Howlader N, Noone AM, Krapcho M, Neyman N, Aminou R, Altekruse SF, Kosary CL, Ruhl J, Tatalovich Z, Cho H, Mariotto A, Eisner MP, Lewis DR, Chen HS, Feuer EJ, Cronin KA: SEER Cancer Statistics Review, 1975-2008, National Cancer Institute. Bethesda, MD, http://seer.cancer.gov/csr/1975-2008/, accessed 17/04/11.
2. Middleton MR, Grob JJ, Aaronson N, Fierlbeck G, Tilgen W, Seiter S, Gore M, Aamdal S, Cebon J, Coates A, Dreno B, Henz M, Schadendorf D, Kapp A, Weiss J, Fraass U, Statkevich P, Muller M, Thatcher N: Randomised phase III study of temozolomide versus dacarbazine in treatment of patients with advanced metastatic malignant melanoma. J Clini Oncol, 18: 158-166, 2000.
3. Lee ML, Tomsu K, Von Eschen KB: Duration of survival for disseminated malignant melanoma: result of a meta-analysis. Melanoma Res, 10: 81-92, 2000.
4. Hersey P, McLeod GR, Thomson DB: Treatment of advanced malignant melanoma with recombinant interferon alpha-2a in combination with DTIC: long-term follow-up of two phase II studies. Br J Haematol, 79: 60-66, 1991.
5. Hill GJ, Krementz ET, Hill HZ: Dimethyl triazeno imidazole carboxamide and combination therapy for melanoma. IV. Late results after complete response to chemotherapy (central oncology group protocols 7130, 7131 and 7131A). Cancer, 53: 1299-1305, 1984.
6. Crosby T, Fish R, Coles B, Mason MD: Systemic treatments for metastatic cutaneous melanoma. Cochrane Database Syst Rev, (2): CD001215, 2000.
7. Miller JD: Surgical excision for single cerebral metastasis? Lancet, 19: 341 (8860): 1566, 1993.
8. Cater SK, Friedman MA: 5-(3,3-dimethyl-1-triazeno)-imidazole-4- carboxamide (DTIC, DIC, NSC-45388) - a new antitumor agent with activity against malignant melanoma. Eur J cancer, 8: 85-92, 1972.
9. Kiebert GM, Jonas DL, Middleton MR: Health-related quality of life in patients with advanced metastatic melanoma: results of a randomised phase III study comparing temozolomide with dacarbazine. Cancer Invest, 21: 821-829, 2003.
10. Chiarion-Sileni V, Guida M, Ridolfi L, Romanini A, Del Bianco P, Pigozzo J, Brugnara S, Colucci G, Ridolfi R, De Salvo GL: Central nervous system failure in melanoma patients: result of a randomised, multicentre phase 3 study of temozolomide-and dacarbazine-based regimens. Br J Cancer, 104: 1816-1821, 2011.
11. Quagliana JM, Stephens RL, Baker LH, Costanzi JJ: Vindesine in patients with metastatic malignant melanoma: a Southwest Oncology Group study. J Clin Oncol, 2: 316-319, 1984.
12. Aamdal S, Wolff I, Kaplan S, Paridaens R, Kerger J, Schachter J, Wanders J, Franklin HR, Verweij J: Docetaxel (Taxotere) in advanced malignant melanoma: a phase II study of the EORTC Early Clinical Trials Group. Eur J Cancer, 30A(8): 1061-1064, 1994.
13. Chapman PB, Einhorn LH, Meyers ML, Saxman S, Destro AN, Panageas KS, Begg CB, Agarwala SS, Schuchter LM, Ernstoff MS, Houghton AN, Kirkwood JM: Phase III multi-centre randomised trial of the Dartmouth regimen versus dacarbazine in patients with metastatic melanoma. J Clin Oncol, 17: 2745-2751, 1999.
14. Rosenberg SA, Yang JC, Topalian SL, Schwartzentruber DJ, Weber JS, Parkinson DR, Seipp CA, Einhorn JH, White DE: Treatment of 283 consecutive patients with metastatic melanoma or renal cell cancer using high-dose bolus interleukin 2. JAMA, 271: 907-913,1994.
15. Atkins MB, Kunkel L, Sznol M, Rosenberg SA: High-dose recombinant interleukin 2 therapy for patients with metasatic melanoma: long-term survival update. Cancer J Sci Am, 6 Suppl 1: S11-14, 2000.
16. Atkins MB, Lotze MT, Dutcher JP, Fisher RI, Weiss G, Margolin K, Abrams J, Sznol M, Parkinson D, Hawkins M, Paradise C, Kunkel L, Rosenberg SA: High-dose recombinant interleukin-2 therapy for patients with metastatic melanoma: analysis of 270 patients treated between 1985 and 1993. J Clin Oncol, 17: 2105-2116, 1999.
17. Sasse AD, Sasse EC, Clark LG, Ulloa L, Clark OA: Sequential biochemotherpy versus chemotherapy for metastatic malignant melanoma. Cochrane Database Syst Rev, 24: CD005413, 2007.
18. Ives NJ, Stowe RL, Lorigan P, Wheatley K: Chemotherapy compared with biochemotherapy for the treatment of metastatic melanoma: a meta-analysis of 18 trials involving 2,621 patients. J Clin Oncol, 25: 5426-5434, 2007.
19. Davies H, Bignell GR, Cox C, Stephens P, Edkins S, Clegg S, Teague J, Woffendin H, Garnett MJ, Bottomley W, Davis N, Dicks E, Ewing R, Floyd Y, Gray K, Hall S, Hawes R, Hughes J, Kosmidou V, Menzies A, Mould C, Parker A, Stevens C, Watt S, Hooper S, Wilson R, Jayatilake H, Gusterson BA, Cooper C, Shipley J, Hargrave D, Pritchard-Jones K, Maitland N, Chenevix-Trench G, Riggins GJ, Bigner DD, Palmieri G, Cossu A, Flanagan A, Nicholson A, Ho JW, Leung SY, Yuen ST, Weber BL, Seigler HF, Darrow TL, Paterson H, Marais R, Marshall CJ, Wooster R, Stratton MR, Futreal PA: Mutations of the BRAF gene in human cancer. Nature, 417: 949-954, 2002.
20. Curtin JA, Fridlyand J, Kageshita TH, Busam K, Kutzner H, Cho K, Aiba S, Bröcker E, LeBoit P, Pinkel D, Bastian B: Distinct sets of genetic alterations in melanoma. N Engl J Med, 353: 2135-2147, 2005.
21. Flaherty KT, Puzanov I, Kim KB, Ribas A, McArthur G, Sosman J, O'Dwyer P, Lee R, Grippo J, Nolop K, Chapman P: Inhibition of mutated, activated BRAF in metastatic melanoma. N Engl J Med, 363: 809-819, 2010.
22. Ribas A, Kim KB, Schuchter LM, Flaherty T, Moschos S, Lawrence D, Hersey P, Kefford R, Chmielowski B, Puzanov I, Li J,Nolop K: BRIM-2: An open-label, multicenter phase II study of vemurafenib in previously treated patients with BRAFV600E mutation-positive melanoma. J Clin Oncol, 29: (suppl; abstr 8509), 2011.
23. Chapman PB, Hauschild A, Robert C, Robert C, Haanen J, Ascierto P, Larkin J, Dummer R, Garbe C, Testori A, Maio C, Hogg D, Lorigan P, Lebbe C, Jouary T, Schadendorf D, Ribas A, O'Day S, Sosman J, Kirkwood J, Eggermon A, Dreno B, Nolop K, Li J, Nelson B, Hou J, Lee R, Flaherty K, McArthur G: Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med, 364: 2507-2516, 2011.
24. Hodi FS, O'Day SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB, Gonzalez R, Robert C, Schadendorf D, Hassel JC, Akerley W, van den Eertwegh AJ, Lutzky J, Lorigan P, Vaubel JM, Linette GP, Hogg D, Ottensmeier CH, Lebbé C, Peschel C, Quirt I, Clark JI, Wolchok JD, Weber JS, Tian J, Yellin MJ, Nichol GM, Hoos A, Urba WJ: Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med, 363: 711-723, 2010.
25. Robert C, Thomas L, Bondarenko I, Weber J, Garbe C, Lebbe C, Baurain J, Testori A, Grob J, Davidson N, Richards J, Maio M, Hauschild A, Miller W, Gascon P, Lotem M, Harmankaya K, Ibrahim R, Francis S, Chen T, Humphrey R, Hoos A, Wolchok J: Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N Engl J Med, 364: 2517-2526, 2011.
26. Graziani G, Tentori L, Navarra P: Ipilimumab: a novel immunostimulatory monoclonal antibody for treatment of cancer. Pharmacol Res, 65: 9-22, 2012.
27. Jure-Kunkel M, Masters G, Girit E, Dito G, Wong T, Wigginton J, Gupta A, Hunt J: Evaluation of combination treatment with a BRAF inhibitor (BM-908662) and CTLA-4 monoclonal antibody in preclinical models. J Clin Oncol, 29: (suppl; abstr e13055), 2011.
28. Agarwala SS, Kirkwood JM, Gore M, Dreno B, Thatcher N, Czarnetski B, Atkins M, Buzaid A, Dimosthenis S, Rankin E: Temozolomide for the treatment of brain metastases associated with metastatic melanoma: a phase II study. J Clin Oncol, 22: 2101-2107, 2004.